HANALL BIOPHARMA CO.,LTD
Financials
Valuation Metrics
HANALL BIOPHARMA CO.,LTD's Market Cap is ₩2.7T. At end of 2025 it was ₩2.3T. Ranked #168 of 2,436 in KR market (top 7%), #140 of 787 on KOSPI (top 18%), #17 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.72T KRW | KR#168/2,436 Sec#17/234 |
| Revenue | 159.06B KRW | KR#1,136/2,436 Sec#69/234 |
| Net Income | -5.08B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 243.83B KRW | KR#1,141/2,436 Sec#80/234 |
| Net Assets | 162.36B KRW | KR#1,051/2,436 Sec#75/234 |
| Employees | 318 | KR#750/2,436 Sec#65/234 |
| Value | ||
| P/B | 16.73x | KR#2,378/2,436 Sec#218/234 |
| P/S | 17.08x | KR#2,318/2,436 Sec#177/234 |
| EV/EBITDA | 8581.45x | KR#1,565/2,436 Sec#112/234 |
| FCF Yield | -0.12% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -3.13% | KR#1,671/2,436 Sec#120/234 |
| ROA | -2.08% | KR#1,708/2,436 Sec#123/234 |
| Op. Margin | 0.20% | KR#1,580/2,436 Sec#111/234 |
| Revenue Growth | 10.73% | KR#893/2,436 Sec#79/234 |
| Earnings Growth | -443.14% | KR#1,616/2,436 Sec#107/234 |
| Financial Health | ||
| Debt Ratio | 150.18% | KR#1,187/2,436 Sec#137/234 |
| Total Debt | 43.17B KRW | KR#1,040/2,436 Sec#73/234 |
| FCF | -3.29B KRW | KR#1,412/2,436 Sec#111/234 |
| Cash | 36.16B KRW | KR#905/2,436 Sec#58/234 |
| Current Ratio | 1.60x | KR#1,233/2,436 Sec#135/234 |
| Net Debt/EBITDA | 22.10x | KR#1,436/2,436 Sec#102/234 |
| Performance | ||
| 1Y Return | 98.47% | KR#144/2,436 Sec#14/234 |
| 1M Return | -12.31% | KR#2,154/2,436 Sec#206/234 |
| From 52W High | -28.77% | KR#576/2,436 Sec#37/234 |
| 1Y MDD | -44.84% | KR#696/2,436 Sec#55/234 |
| Trading | ||
| Volume | 572,420 shares | KR#417/2,436 Sec#35/234 |
| Foreign Own. | 3.14% | KR#987/2,436 Sec#96/234 |
| Per Share | ||
| EPS | -97 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,197 KRW | KR#1,776/2,436 Sec#136/234 |
Company Info
Hanall Biopharma is a pharmaceutical company established in 1973 and listed on the Korea Exchange in 1989. It manages overseas clinical trials and licensing for new drugs through its U.S. subsidiary, HPI. The company manufactures and sells over 160 pharmaceutical products for endocrine, circulatory, and other systems, while researching diverse new drugs, including antibody-based therapies for autoimmune diseases. By strengthening its R&D infrastructure with First-in-Class biosimilar drug research, dedicated personnel, and expanded facilities, Hanall Biopharma is enhancing its global market competitiveness. It is headquartered in Daedeok-gu, Daejeon.